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Central Poststroke Pain syndrome (CPSP) can occur due to disruption of the somatosensory pathways of
the brain at any level such as the thalamus, medulla, or cerebral cortex. It is characterized by sensory
abnormalities and hyperesthesia in the part of the body correlating to the central lesion. The treatment of this
pain syndrome is often difficult, and it does not usually respond to traditional analgesics. The first line of
treatment is drugs aimed at lowering neuronal hyperexcitability, for example, amitriptyline or lamotrigine,
with gabapentin considered a second line.
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D
ejerine Roussy syndrome or thalamic pain
syndrome is a rare form of central pain syn-
drome occurring as a result of a vascular lesion
in the sensory nucleus of the thalamus. It is characterized
by sensory abnormalities and hyperesthesia in the region
of the body correlating to the cerebrovascular lesion.
The treatment of this pain syndrome is often difficult.
Therapies that have been found to be of benefit include
medications that reduce neuronal hyperexcitability of the
neurons, for example, amitriptyline and lamotrigine.
Case
A 63-year-old right handed male with a history of
hypertension, diabetes mellitus, and active tobacco abuse
presented with a 5-day history of right-sided numbness
and sharp pain in his left lower extremity for 1 day. He
denied symptoms of fever, chills, seizure-like activity,
nausea, vomiting, weakness, bowel or bladder inconti-
nence, slurring of speech, loss of consciousness, chest
pain, shortness of breath, or palpitations. Additional
medical history included anxiety, depression, and chronic
back pain. On examination, he was alert and oriented to
person, place, and time. His vital signs revealed marked
elevation of blood pressure to 190/102 mmHg, pulse rate
of 88 beats per minute (regular), and temperature 37.88C.
On neurological examination, he had hyperesthesia on
the right side of the body demonstrated by exaggerated
pain on light touch. No facial asymmetry, cranial nerve
involvement, or any motor deficits were noted. Babinski
reflexes were bilaterally down going and deep tendon
reflexeswerebilaterally equal. CTscanofthe headshowed
right-sided old infarct in the corona radiata. Diffusion-
weighted magnetic resonance imaging (MRI) of the
brain revealed subacute infarcts in left corona radiata
and punctate subacute lacunar infarct in left thalamus
(Figs. 1 and 2). Echocardiogram showed no evidence of
thrombus in the heart chambers or atrial fibrillation/
flutter, and Doppler imaging of the carotid artery was
within normal limits. His right-sided hyperesthesia was
attributed to thalamic stroke. Gabapentin was started at
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Fig. 1. Axial Diffusion-weighted MR image showing punc-
tate focus of increased signal in Lt. posteroinferolateral
region of thalamus (arrow).
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three times daily. His pain responded well to morphine
initially which was later transitioned to tramadol. Over
the next 4 days, he reported a marked decrease in his right-
sided discomfort. At 6 months’ follow-up, his pain has
been fairly well controlled with gabapentin and tramadol.
Discussion
Thalamic pain syndrome is a rare condition, first
described by Dejerine and Roussy in 1906, which
develops after a thalamic stroke. It is one of the causes
of Central Poststoke Pain syndrome (CPSP) which occurs
as a result of a vascular lesion of the ventroposterolateral
nucleus of the thalamus. A lesion at any level of the
spinothalamic tract is thought to be essential for the
development of thalamic CPSP (1). Though common
after ischemic or hemorrhagic strokes involving the
thalamus, CPSP can occur secondary to disruption of
the somatosensory pathways of the brain at any level,
that is, thalamus, medulla, or cerebral cortex (2).
Diagnosis relies on a detailed history, accurate general
and neurological examination, and imaging of the brain
with the exclusion of other possible causes of pain (2, 3).
It is important to distinguish CPSP from other types of
pain that can occur after a stroke, including persistent
headache, painful contractures, hemiplegic shoulder pain,
and other painful musculoskeletal conditions.
The syndrome commonly causes numbness and tin-
gling in the part of the body corresponding to the lesion
in the brain. Patients can present with sensory deficits on
one side of the body, mild motor deficits, abnormal
movements, and other minor stroke symptoms. Weeks to
months later, patients can present with severe and chronic
pain disproportional to an environmental stimulus, called
dysesthesia or allodynia. In one prospective study, 63% of
patients developed these symptoms within 1 month, 19%
within 6 months, and the rest 19% after 6 months of
having the stroke (4). Patients often suffer chronic pain
which can be disabling, often described as sharp, stab-
bing, or burning. The area of pain corresponds to the
stroke-associated sensory deficit with pinprick or thermal
sensation (3).
Neuropathic pain, in contrast to the regular pain
occurring from the triggering of nociceptors, arises
from abnormal pain signaling within the nervous system
itself. Diagnosis of the syndrome in itself can be reassur-
ing to the patient. To date, only a few randomized
controlled studies on the treatment of CPSP have been
published, showing, at best, modest treatment response
to some agents. None of the agents, however, have been
found to have any preventive benefit following an acute
thalamic stroke (2). Currently, agents directed at lowering
neuronal hyperexcitability, such as amitriptyline and
lamotrigine, are considered first line as they have been
shown to have moderate benefit in some randomized
controlled trials (RCTs) (3, 5, 6). There have been no
clinical trials using gabapentin specifically for CPSP. It
has proven efficacy for other neuropathic pain syndromes
such as diabetic neuropathy. It is considered a second-line
agent in clinical practice. A recent RCT, including 219
patients, failed to show any improvement in pain scales in
the pregabalin treatment arm (3). Opioids and lidocaine
have been used with variable efficacy. Although not
proven in clinical trials, combination therapy, as fre-
quently used in clinical practice, may be effective.
Noninvasive stimulation therapy can be considered in
refractory cases (3, 7, 8). In conclusion, CPSP remains a
significant impediment in the lives of certain poststroke
patients, with little in the way of effective treatment in the
standard armamentarium, and further research is needed
into novel treatments.
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